Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 74,999 |
|
|||||
| News | - | ||||||
| Day High | 4.1831 | Low High |
|||||
| Day Low | 3.77 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Mural Oncology PLC | MURA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.02 | -0.51% | 3.90 | 13:53:43 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.93 | 3.77 | 4.1831 | 3.92 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,037 | 74,999 | $ 3.93 | $ 294,692 | - | 3.23 - 17.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:54:00 | 30 | $ 3.88 | USD |
Mural Oncology PLC Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 66.00M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Mural Oncology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MURA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.80 | 4.1831 | 3.64 | 3.84 | 77,282 | 0.10 | 2.63% |
| 1 Month | 3.87 | 4.1831 | 3.44 | 3.70 | 131,625 | 0.03 | 0.78% |
| 3 Months | 4.60 | 5.623 | 3.44 | 4.56 | 216,146 | -0.70 | -15.22% |
| 6 Months | 16.69 | 17.00 | 3.23 | 4.35 | 449,945 | -12.79 | -76.63% |
| 1 Year | 16.69 | 17.00 | 3.23 | 4.35 | 449,945 | -12.79 | -76.63% |
| 3 Years | 16.69 | 17.00 | 3.23 | 4.35 | 449,945 | -12.79 | -76.63% |
| 5 Years | 16.69 | 17.00 | 3.23 | 4.35 | 449,945 | -12.79 | -76.63% |
Mural Oncology Description
| Mural Oncology¿s pipeline is built to address difficult-to-treat tumor types where checkpoint inhibitors are not effective. The Company¿s lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 (rhIL-2), while mitigating the hallmark toxicities of native IL-2 in difficult-to-treat cancers with high unmet need. Nemvaleukin is currently in two potentially registrational studies: one for the treatment of mucosal melanoma as a monotherapy and one for the treatment of platinum-resistant ovarian cancer (PROC) in combination with pembrolizumab. |
